Omnicell (NASDAQ:OMCL) Trading Down 4.9% – Time to Sell?

Shares of Omnicell, Inc. (NASDAQ:OMCL) fell 4.9% on Wednesday . The stock traded as low as $38.89 and last traded at $38.6790. 59,761 shares changed hands during trading, a decline of 90% from the average session volume of 602,368 shares. The stock had previously closed at $40.69.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on OMCL. Wells Fargo & Company upped their price objective on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Craig Hallum reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Benchmark restated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. Finally, UBS Group set a $60.00 price objective on shares of Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $59.86.

Omnicell Stock Down 4.5%

The firm has a 50-day moving average of $40.15 and a 200 day moving average of $41.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 88.22, a PEG ratio of 1.09 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the firm posted $0.26 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 15,520 shares of company stock valued at $607,610. Insiders own 2.92% of the company’s stock.

Institutional Trading of Omnicell

A number of hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in Omnicell during the second quarter worth approximately $26,000. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Omnicell during the fourth quarter worth approximately $58,000. Parkside Financial Bank & Trust lifted its holdings in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after purchasing an additional 1,264 shares during the last quarter. Finally, First Horizon Corp lifted its holdings in Omnicell by 54.6% during the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after purchasing an additional 564 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.